← Back to Search

Passive Referral to Treatment Control for Opioid Use Disorder (RIMO Trial)

N/A
Waitlist Available
Led By Christine E Grella, Ph.D.
Research Sponsored by Chestnut Health Systems
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Experienced an opioid overdose reversed with naloxone administered by first responders on a participating team within the past week
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights

RIMO Trial Summary

This trial is testing a new intervention for people who have overdosed on opioids and been given naloxone by first responders, but have not entered into MAT. The intervention is called Recovery Initiation and Management after Overdose (RIMO), and it is designed to help people connect to treatment and recovery support.

Who is the study for?
This trial is for adults in Chicago who've had an opioid overdose reversed with naloxone by first responders in the past week, are not currently in treatment, and have a positive screen for Opioid Use Disorder. They must be over 18, able to consent, and speak English.Check my eligibility
What is being tested?
The study compares two approaches: usual referral to Medication-Assisted Treatment (MAT) versus Recovery Initiation and Management after Overdose (RIMO), which includes assertive linkage to MAT and ongoing recovery support.See study design
What are the potential side effects?
Since this trial focuses on referral methods rather than medications, there aren't direct side effects from interventions like drugs. However, participants may experience stress or anxiety during recovery initiation.

RIMO Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I was revived from an opioid overdose with naloxone by first responders within the last week.

RIMO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Length of Staying on Medication
MAT Days
MAT Time to Initiation
Secondary outcome measures
Cost of Health Care Utilization
Mental Health: Externalizing Symptoms
Mental Health: Internalizing Symptoms
+6 more

RIMO Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Recovery Initiation and Management after Overdose (RIMO)Experimental Treatment2 Interventions
Participants assigned to the RIMO arm will meet with Linkage Managers (LM), who will use motivational interviewing (MI) techniques to: 1) identify the need for treatment and barriers to going, 2) discuss with patients the benefits of their decision to go to treatment, including activities they might enjoy as well as things they do not like about their alcohol/substance use, 3) provide personalized feedback to participants about the status of their condition based on responses to the assessment instruments, 4) help participants resolve ambivalence about their use and move them toward a commitment to change by accessing additional care, 5) address existing barriers to treatment (e.g., childcare, transportation), 6) schedule a treatment appointment, and 7) facilitate medication assisted treatment re-entry and engagement.
Group II: Passive Referral ControlActive Control1 Intervention
Participants will be given information on recently expanded and publicly-funded MAT treatment in their community.

Find a Location

Who is running the clinical trial?

Chestnut Health SystemsLead Sponsor
20 Previous Clinical Trials
23,034 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,447 Previous Clinical Trials
2,593,815 Total Patients Enrolled
Christine E Grella, Ph.D.Principal InvestigatorChestnut Health Systems

Media Library

Recovery Initiation and Management after Overdose (RIMO) Clinical Trial Eligibility Overview. Trial Name: NCT03895827 — N/A
Opioid Use Disorder Research Study Groups: Recovery Initiation and Management after Overdose (RIMO), Passive Referral Control
Opioid Use Disorder Clinical Trial 2023: Recovery Initiation and Management after Overdose (RIMO) Highlights & Side Effects. Trial Name: NCT03895827 — N/A
Recovery Initiation and Management after Overdose (RIMO) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03895827 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this clinical research still ongoing?

"Affirmative. Clinicaltrials.gov confirms that the research project, which was first registered on April 1st 2022 is presently recruiting participants from one site with a total of 350 individuals required for completion."

Answered by AI

What is the current participant count in this investigation?

"Correct. According to the data on clinicaltrials.gov, this medical experiment is actively recruiting participants as of July 18th 2022, having been initially posted a few months prior on April 1st. A total of 350 patients are being sought out between one site location."

Answered by AI

What is the primary aim of this research?

"The primary measure of the clinical study, monitored over 9 months, is Time to Initiation. Secondary objectives include calculating Cost of Health Care Utilization using economic estimates and inflation rate data; gauging Mental health: Externalizing Symptoms with a 0-6 scale based on attention deficit disorders, hyperactivity, conduct issues or gambling problems; and measuring Time to Relapse in days from randomisation to next opiate/heroin use as determined by interviews and urine tests."

Answered by AI
~19 spots leftby Jun 2024